ADH1B and ALDH Gene Variants and Lung Cancer Risk

NCT07273279 | Not Yet Recruiting

• 2 other identifiers: KMUHIRB-E(I)-20250145113-2314-B-037 -070 -MY3
• Study Type: observational
• Target: 100,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

Lung cancer in never-smokers is increasingly recognized as a disease influenced by genetic susceptibility. Aldehyde-metabolizing enzymes, including the ALDH gene family and ADH1B, play key roles in detoxifying reactive aldehydes that can damage DNA and promote oxidative stress. In this study, we will examine whether ten selected genetic variants, nine single nucleotide polymorphisms (SNPs) across five ALDH family genes and one variant in ADH1B are associated with the risk of lung cancer and its major subtypes. Limited epidemiological evidence is currently available on the association between these aldehyde-metabolizing gene variants and lung cancer. This research aims to clarify their potential contribution to the development of lung cancer, particularly among never-smokers.

Conditions

Condition/Disease; Lung Cancer (Diagnosis); Lung Adenocarcinoma

Keywords

ALDH2; ADH1B; Lung cancer

Outcome Measures

Primary Outcomes (1)

• Lung cancer status (case vs control)

  Lung cancer status determined by pathology-confirmed diagnosis at the time of case identification

  Not applicable (baseline status)

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Lung cancer status determined by pathology-confirmed diagnosis at the time of case identification

You may qualify if:

• Incident lung cancer cases confirmed by pathology and healthy adult over age of 18 years.

You may not qualify if:

• Individuals with incomplete data will not be included as study participants.

Sponsors & Collaborators

• Kaohsiung Medical University: lead

MeSH Terms

Conditions

Disease; Lung Neoplasms; Adenocarcinoma of Lung

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Central Study Contacts

Tzu Yu Pan, PhD

CONTACT

886-3221806; R990174@gap.kmu.edu.tw

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Postdoctoral Researcher

Study Record Dates

• First Submitted: November 26, 2025
• First Posted: December 9, 2025
• Study Start: January 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: December 9, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share